Omeprazole + domperidone


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Acid-related disorder, mild to moderate GERD, heartburn and dyspepsia 1 cap twice daily or as directed.
Contraindications
Pregnancy. Domperidone is contraindicated in conditions associated with rise in prolactin level. Omeprazole is contraindicated in hypersensitive patients.
Special Precautions
Domperidone can cause a rise in serum prolactin level resulting in galactorrhoea in females and less frequently gynaecomastia in males. Hypertensive crisis may occur in patients with phaeochromocytoma. Renal impairment or those at risk of fluid retention. Hepatic impairment; elderly. Exclude the possibility of malignancy if gastric ulcer is suspected, before initiating treatment with omeprazole, it may mask symptoms and delay diagnosis. Monitor patients on warfarin or phenytoin therapy, reduce dose if necessary.
Adverse Reactions
Domperidone: Dry mouth, transient skin rash, itching, headache, diarrhoea and rarely nervousness. Omeprazole: Anaemia, eosinopaenia, urinary tract infection, skin rash, urticaria and pruritus, diarrhoea, headache, constipation, nausea, vomiting, flatulence and abdominal pain, dizziness and lightheadedness, somnolence, insomnia and vertigo, reversible confusion, agitation, depression and hallucinations, arthritic and myalgic symptoms.
Drug Interactions
Anticholinergics may antagonize beneficial effects of domperidone in reflux oesophagitis and dyspepsia. Decreased bioavailability of domperidone after prior admin of cimetidine or Na bicarbonate. Delayed elimination of diazepam, phenytoin and warfarin with omeprazole.
ATC Classification
A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
A02BC01 - omeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by CIMS based on omeprazole + domperidone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in